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Ischemic heart disease (IHD) persists as a leading cause of premature death and disability 29 
worldwide [1]. IHD may present as acute myocardial infarction (MI) or manifest as a chronic 30 
coronary syndrome [2]. IHD is increasingly recognized as a concomitant problem in systemic 31 
health problems, such as rheumatoid arthritis. Coronary atherosclerosis is a major cause of 32 
IHD and the historical primacy of coronary artery disease (CAD) leads some clinicians to 33 
view coronary heart disease (CHD) and IHD as synonymous, interchangeable terms. 34 
Emerging clinical evidence indicates this is far from being the case and a major reappraisal is 35 
warranted [3]. 36 
Under-recognition of coronary microvascular disease: time for a reappraisal  37 
Coronary microvascular dysfunction (CMD) has, historically, been under recognized, not 38 
least since the microvessels are invisible. This simple issue has underpinned key 39 
misconceptions about IHD and major knowledge gaps relating to CMD [3]. Atherosclerosis 40 
is the major cause of CAD and the pathogenesis, prognosis and treatment of these problems 41 
are well established [2]. In recent years, new insights into the causes and consequences of 42 
IHD have called into question the CAD stenosis-centred/CHD paradigm. Most recently, the 43 
ISCHEMIA trial results were reported at the Scientific Sessions of the American Heart 44 
Association (November 16, 2019) [5, 6]. The central hypothesis of the ISCHEMIA trial was 45 
that in patients with angina and moderate-severe myocardial ischaemia, compared with initial 46 
non-invasive, medical management, a routine invasive strategy with cardiac catheterisation 47 
followed by coronary revascularisation plus optimal medical therapy, would improve 48 
prognosis. After 3.3 years follow-up, there was no difference in the primary endpoint 49 
between the randomized groups [6]. This trial did have limitations. Under-recruitment and a 50 
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lower than expected event rate reduced the statistical power for analysis of the primary 51 
outcome that ultimately led to a belated, yet prespecified change in the primary composite 52 
outcome. Longer term follow-up with accrual of more events may provide new insights. 53 
Nonetheless, ISCHEMIA is the largest study of its kind, and the results call into question the 54 
benefits of coronary revascularization in patients with myocardial ischaemia. 55 
Clinical relevance of coronary microvascular dysfunction 56 
Coronary microvascular dysfunction is increasingly implicated as a relevant cause of IHD 57 
[6]. Angina secondary to myocardial ischaemia may occur in patients with no obstructive 58 
CAD (INOCA). In fact, around 1 in 5 patients presenting with known or suspected angina 59 
have obstructive CAD, as revealed by anatomical imaging with CT coronary angiography 60 
(CTCA) [7] (Figure 1). In the clinic, the cause of the angina is uncertain in the majority of 61 
affected patients, most of whom are women [7,8]. This becomes all the more relevant given 62 
that CTCA-guided management leads to worse angina and quality of life overall, contrary to 63 
what might be anticipated [9]. The Coronary Microvascular Function and CT Coronary 64 
Angiogram (CorCTCA) study is currently examining the prevalence and clinical significance 65 
of CMD in patients with angina but no obstructive CAD, as defined by CTCA [10]. The 66 
recent Coronary Microvascular Angina (CorMicA trial) served evidence that undertaking 67 
tests of coronary vascular function during clinically-indicated coronary angiography 68 
identifies relevant endotypes (microvascular angina, vasospastic angina, non-cardiac chest 69 
pain) and targeted therapy was associated with improvements in angina and quality of life at 70 
6- [11] and 12-months [12] (Figure 2). Considering acute myocardial infarction, about 1 in 10 71 
patients presenting with MI have no obstructive coronary arteries (MINOCA) [13]. 72 
Microvascular and vasospastic disease are also implicated. Considering the natural history, 73 
INOCA and MINOCA may underlie the development of heart failure with preserved ejection 74 
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fraction (HFPEF) [14], which is an increasingly recognized, prevalent cause of heart failure. 75 
Coronary microvascular disease may be part of a systemic continuum of microvascular 76 
disease, with multiple affected organ beds [15]. Small vessel disease in the heart and brain 77 
links INOCA with vascular dementia [15]. The deleterious effects of vascular risk factors, 78 
such as hypertension, obesity, smoking and diabetes are relevant, and genetic associations 79 
[4], notably leading to increased exposure to endothelin-1 [16], are also implicated. CMD is 80 
causally implicated in multiple systemic conditions including the cardiotoxicity of 81 
chemotherapy, systemic inflammatory conditions, such as rheumatoid arthritis, heart failure 82 
and pregnancy [17]. Sex associations are also relevant [18]. Obstructive CAD typically 83 
associates with male sex whereas small vessel disease associates with female sex [7,8,10,11]. 84 
Since anatomical imaging with CTCA is diagnostically most useful for identifying and 85 
excluding CAD and compared with ischaemia testing, least useful for the diagnosis of CMD, 86 
an all-comers strategy based on CTCA introduces a sex bias [3]. Under-recognition and 87 
under-treatment of heart disease in women is a hot topic [17,18], and more research seems 88 
warranted. 89 
Some of the persisting, clinically-relevant questions are: 1) In INOCA and MINOCA, is 90 
myocardial ischaemia the consequence and/or cause of microvascular dysfunction? Is chronic 91 
myocardial ischaemia therapeutically modifiable? Is microvascular dysfunction a common 92 
problem after successful revascularization? If so, what are the mechanisms underlying 93 
microvascular dysfunction, what treatments might be disease-modifying and beneficial to 94 
patients? Is CMD other systemic conditions are modifiable target? What is the natural history 95 
of CMD? The clinical relevance of microvascular dysfunction in patients with flow-limiting 96 
CAD is being investigated in the DEFINE-FLOW study [19], due to be reported in 2020. The 97 
Changes in Ischemia and Angina Over 1 Year Among ISCHEMIA Trial Screen Failures 98 
With no Obstructive CAD on Coronary CT Angiography (CIAO) substudy will also be 99 
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informative [20].  100 
Accordingly, CMD has generated substantial interest in the clinical and basic science 101 
communities in recent years. This Spotlight Issue brings together internationally leading 102 
thought-leaders, researchers and their trainees. The authors have a broad range of 103 
backgrounds including basic science, translational research and clinical studies. Their remit is 104 
to focus on ‘hot topics’ in CMD and give perspectives on the science. 105 
 The Spotlight Issue begins with a Position Paper, “Coronary Microvascular 106 
Dysfunction in Cardiovascular Disease”, from the European Society of Cardiology (ESC) 107 
Working Group on Coronary Pathophysiology and the Microcirculation [21]. The Position 108 
Paper by Drs. Padro, Badimon and coauthors highlights, firstly, updated evidence on the 109 
pathophysiological consequences of microvascular dysfunction in the heart. Secondly, they 110 
focus on the relevance of cardiovascular risk factors and co-morbid conditions for 111 
microcirculatory dysfunction. Thirdly, they highlight the clinical consequences of CMD, 112 
which is not a benign problem. They conclude that clinical strategies should prioritise 113 
detection of CMD which in turn will help in the stratification of cardiovascular in support of 114 
precision medicine.  115 
 The first article focuses on experimental models of CMD. Duncker et al. discuss the 116 
benefits and pitfalls of existing small and large animal models of CMD, with a specific focus 117 
on metabolic disturbances which may be experimentally induced or spontaneous [22]. They 118 
provide a comprehensive description of relevant experimental research involving a range of 119 
species. They also highlight the value of experimental models for identifying novel 120 
therapeutic targets and for the subsequent development and testing of novel therapeutic 121 
interventions. 122 
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The next article focuses on “Diagnosis of coronary microvascular dysfunction in the clinic”. 123 
Ong et al. [23] cover the diagnosis of CMD in an article that discusses the invasive and non-124 
invasive methods for the assessment of CMD in humans. They highlight an integrative 125 
approach for assessing coronary vascular function using a diagnostic guidewire initially and 126 
then pharmacological reactivity testing using intracoronary administration of acetylcholine 127 
(ACh). They highlight the IDP developed by Berry and Ford [11] as the current gold standard 128 
for assessing coronary vascular function. A review from Bairey Merz et al. [24] on 129 
‘Treatment of CMD’, provides a comprehensive overview of pharmacotherapies with 130 
potential efficacy in alleviating CMD. The article highlights pivotal clinical trials in CMD, 131 
such as CorMicA [11] and WARRIOR (ClinicalTrials.gov Identifier: NCT03417388). In 132 
addition, they highlight novel therapeutics, including gene and cell-based therapies.  133 
 The Spotlight also includes articles on CMD in different cardiovascular disease 134 
settings. Sechtem et al. [25] focus on CMD in stable IHD, including INOCA and obstructive 135 
CAD. They focus on challenging concepts including CMD in the absence of atherosclerosis,  136 
CMD detection, microvascular spasm, collateral connections, and the prognostic importance 137 
of global coronary flow reserve.  Konijnenberg, van Royen et al. [26] focus on the 138 
pathophysiology and diagnosis of CMD in acute myocardial infarction. The authors state that 139 
the current standard of care, primary percutaneous coronary intervention (PCI), successfully 140 
restores coronary blood flow in the vast majority of patients yet most also have evidence of 141 
failed myocardial perfusion, revealed as microvascular obstruction (MVO) using magnetic 142 
resonance imaging. MVO confers an adverse prognosis and in spite of multiple therapeutic 143 
trials, MVO has no evidence-based treatment and has an unmet therapeutic need. The 144 
manuscript also discusses pre-clinical models. Camici et al. [27] discuss the mechanisms by 145 
which CMD is a contributing factor to the transition from left ventricular hypertrophy heart 146 
failure with either a reduced or preserved ejection fraction. Relevant mechanisms are 147 
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discussed. CMD in genetic cardiomyopathy is also described. Maas and colleagues [28] 148 
describe the pathogenic role of CMD in the setting of other cardiac or systemic conditions. 149 
They highlight diabetes mellitus, obesity and vascular inflammation as relevant causes of 150 
CMD. 151 
A further disease modifier of CMD pathology is sex [17,18]. Women who are under 152 
investigation for myocardial ischemia are more likely to have non-obstructive CAD on 153 
coronary angiography and CMD is relevant. Meta et al. [29] explore sex-associations of 154 
INOCA, MINOCA, symptoms, risk factors and, intriguingly, sex-specific factors such as 155 
inflammation, mental stress, autonomic and neuro-endocrine dysfunction that may cause 156 
women to be more likely to develop CMD relative to men. Sex differences have major 157 
implications for both diagnosis and treatment of cardiovascular disease. 158 
We recognize and thank experts from the COVADIS (Coronary Vasomotor Disorders 159 
International Study Group) and ESC Working Group on Coronary Pathophysiology and 160 
Microcirculation for their collaboration. The Editors hope that by bringing this collection of 161 
articles together, the Spotlight will enhance interest for research in CMD. This problem 162 
pervades human disease, mechanisms are poorly understood and specific treatments are 163 
lacking. CMD presents an exciting field for discovery and translation to reduce the unmet 164 
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Legend: ANOCA – angina with no obstructive coronary arteries; CAD – coronary artery 287 
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